FDA will publicly scold drug companies that try to derail generics

The FDA’s new tactic for driving down prescription drug costs: publicly shaming them by “shining a light on situations where drug makers may be pursuing gaming tactics to delay generic competition.” Drug companies that try to scuttle generic competition will be named on the FDA’s Website.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.